CO6150188A2 - Uso de teencteplasa para tratar un ictus isquemico agudo - Google Patents

Uso de teencteplasa para tratar un ictus isquemico agudo

Info

Publication number
CO6150188A2
CO6150188A2 CO09020350A CO09020350A CO6150188A2 CO 6150188 A2 CO6150188 A2 CO 6150188A2 CO 09020350 A CO09020350 A CO 09020350A CO 09020350 A CO09020350 A CO 09020350A CO 6150188 A2 CO6150188 A2 CO 6150188A2
Authority
CO
Colombia
Prior art keywords
approximately
administered
minutes
stroke
dose
Prior art date
Application number
CO09020350A
Other languages
English (en)
Spanish (es)
Inventor
Peter Kuebler
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6150188(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CO6150188A2 publication Critical patent/CO6150188A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CO09020350A 2006-08-29 2009-02-27 Uso de teencteplasa para tratar un ictus isquemico agudo CO6150188A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29

Publications (1)

Publication Number Publication Date
CO6150188A2 true CO6150188A2 (es) 2010-04-20

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09020350A CO6150188A2 (es) 2006-08-29 2009-02-27 Uso de teencteplasa para tratar un ictus isquemico agudo

Country Status (21)

Country Link
US (2) US20080107641A1 (cg-RX-API-DMAC10.html)
EP (1) EP2056856B1 (cg-RX-API-DMAC10.html)
JP (1) JP5785687B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090045405A (cg-RX-API-DMAC10.html)
CN (1) CN101505785A (cg-RX-API-DMAC10.html)
AU (1) AU2007290277B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0716143A2 (cg-RX-API-DMAC10.html)
CA (1) CA2661012C (cg-RX-API-DMAC10.html)
CO (1) CO6150188A2 (cg-RX-API-DMAC10.html)
EA (1) EA015573B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099178A (cg-RX-API-DMAC10.html)
IL (2) IL196987A (cg-RX-API-DMAC10.html)
MX (1) MX2009001918A (cg-RX-API-DMAC10.html)
MY (1) MY163119A (cg-RX-API-DMAC10.html)
NO (1) NO342302B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ574767A (cg-RX-API-DMAC10.html)
SG (3) SG10201501498VA (cg-RX-API-DMAC10.html)
TW (1) TWI439282B (cg-RX-API-DMAC10.html)
UA (1) UA97486C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008027687A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200900957B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法
EP3483140A1 (en) 2007-04-13 2019-05-15 Diffusion Pharmaceuticals LLC Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
EP2384141A1 (en) * 2008-12-24 2011-11-09 Koninklijke Philips Electronics N.V. System, method and apparatus for cardiac intervention with mr stroke detection and treatment
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
CA2772097C (en) * 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
EP2654770B1 (en) * 2010-12-23 2018-07-11 Gennova Biopharmaceuticals Ltd. Pharmaceutical compositions of tenecteplase
WO2014062888A1 (en) * 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
CA2901443A1 (en) 2013-03-15 2014-09-25 Insera Therapeutics, Inc. Vascular treatment devices and methods
US8715315B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment systems
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
DK3209767T3 (da) * 2014-10-21 2020-11-02 Gennova Biopharmaceuticals Ltd Hidtil ukendt oprensningsfremgangsmåde til isolering og kommerciel fremstilling af rekombinant tnk-tpa (tenecteplase)
EP3416568A4 (en) 2016-02-16 2019-10-16 Insera Therapeutics, Inc. SUCTION DEVICES AND ANCHORED FLOW REVERSING DEVICES
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US12458379B2 (en) * 2017-01-24 2025-11-04 Boston Scientific Scimed, Inc. Method for the treatment of thromboembolism
WO2018210860A1 (en) * 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
WO2021158799A1 (en) * 2020-02-04 2021-08-12 The Regents Of The University Of Colorado, A Body Corporate Prophylactic uses of annexin a2
CA3171307A1 (en) * 2020-02-19 2021-08-26 Nono Inc. Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
CN115487294A (zh) * 2022-07-12 2022-12-20 上海丰华天力通生物医药有限公司 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3559559B2 (ja) 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法

Also Published As

Publication number Publication date
CN101505785A (zh) 2009-08-12
IL248176A0 (en) 2016-11-30
TW200817033A (en) 2008-04-16
CA2661012C (en) 2019-03-19
US9023346B2 (en) 2015-05-05
US20120164157A1 (en) 2012-06-28
EP2056856A2 (en) 2009-05-13
KR20090045405A (ko) 2009-05-07
SG174753A1 (en) 2011-10-28
MX2009001918A (es) 2009-03-06
TWI439282B (zh) 2014-06-01
BRPI0716143A2 (pt) 2013-11-26
EA015573B1 (ru) 2011-10-31
IL196987A0 (en) 2011-08-01
WO2008027687A2 (en) 2008-03-06
AU2007290277A1 (en) 2008-03-06
WO2008027687A3 (en) 2008-05-22
SG10201501498VA (en) 2015-04-29
JP2010502629A (ja) 2010-01-28
ZA200900957B (en) 2010-05-26
AU2007290277B2 (en) 2013-04-11
ECSP099178A (es) 2009-06-30
IL196987A (en) 2016-10-31
MY163119A (en) 2017-08-15
US20080107641A1 (en) 2008-05-08
CA2661012A1 (en) 2008-03-06
JP5785687B2 (ja) 2015-09-30
SG10201804944XA (en) 2018-07-30
UA97486C2 (ru) 2012-02-27
NO342302B1 (no) 2018-04-30
HK1131054A1 (en) 2010-01-15
NO20091296L (no) 2009-05-28
EP2056856B1 (en) 2015-01-14
EA200970237A1 (ru) 2009-08-28
NZ574767A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
ECSP21051833A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
ECSP099178A (es) Método de tratamiento del ictus con un trombolítico
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
CR11724A (es) Agente para tratar enfermedades
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
MX2009005798A (es) Recuperacion de apoplejia.
ZA202000028B (en) Use of vibegron to treat overactive bladder
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
PL1677806T3 (pl) Sposoby leczenia ostrego i nadmiernego skręcenia i naciągnięcia przy użyciu kwasu hialuronowego
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno